Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

acs dobfar spa - ceftazidime (ceftazidime pentahydrate), avibactam (avibactam sodium) - powder for solution for infusion - 2g+ 0,5g

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g - powder for injection - 1 g - active: ceftazidime pentahydrate 1.164 g equivalent to ceftazidime 1.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g - powder for injection - 2 g - active: ceftazidime pentahydrate 2.329 g equivalent to ceftazidime 2.0 g excipient: sodium carbonate - indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycoside in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used. indications include: - severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, for example infected burns. - respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. - severe ear, nose and throat infections: for example, otitis media, mastoiditis. - urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. - skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. - gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. - bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis. - infections associted with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd)

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - ceftazidime pentahydrate 1160mg equivalent to ceftazidime 1000 mg - powder for injection - 1 g - active: ceftazidime pentahydrate 1160mg equivalent to ceftazidime 1000 mg excipient: sodium carbonate

New Zealand - English - Medsafe (Medicines Safety Authority)

multichem nz limited - ceftazidime pentahydrate 2320mg equivalent to ceftazidime 2000 mg - powder for injection - 2 g - active: ceftazidime pentahydrate 2320mg equivalent to ceftazidime 2000 mg excipient: sodium carbonate

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing spa - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 500mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxosmithkline manufacturing s.p.a. - ceftazidime (ceftazidime pentahydrate) - powder for solution for injection/infusion - 1000mg

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile);   - powder for injection - 1 g - active: ceftazidime pentahydrate 1.1648 g equivalent to ceftazidime 1 g (sterile)   excipient: sodium carbonate - indicated for the treatment of adults and children including neonates with single or multiple infections caused by susceptible organisms. may be used alone as first choice medicine before the results of sensitivity tests are available. may be used in combination with an aminoglycoside or most other beta-lactam antibiotics. may be used with an antibiotic against anaerobes when the presence of bacteroides fragilis is suspected. susceptibility to ceftazidime will vary with geography and time and local susceptibility data should be consulted where available (see section 5.1 pharmacodynamic properties). indications include: - severe infections e.g. - septicaemia, bacteraemia, peritonitis, meningitis. - infections in immunosuppressed patients. - infections in patients in intensive care, e.g. infected burns. - respiratory tract infections including lung infections in cystic fibrosis. - ear, nose and throat infections. - urinary tract infections. - skin and soft tissue infections. - gastrointestinal, biliary and abdominal infections. - bone and joint infections. - infections associated with haemo- and peritoneal dialysis and with continuous ambulatory peritoneal dialysis (capd).